AtheroGenics Drops AGIX-4207 After Failed Rheumatoid Arthritis Phase II Trial
This article was originally published in The Pink Sheet Daily
Placebo yielded a greater ACR 20 response rate than any of three AGIX-4207 dosing arms in the Phase II trial. The company will turn to second-generation compounds that are part of its vascular protectant program.
You may also be interested in...
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.
The company formerly known as Valeant, put together by a series of mergers, is ready to spin out the legacy Bausch + Lomb eyecare business that it used in its rebranding.